Floatz logo

DALPICICLIB ISETIONATE

Neoplasm

Hebei Medical University Fourth HospitalSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Neoplasm cohort.

Asset / SponsorPhaseRating
Inno-206
The First Affiliated Hospital of Soochow University
Phase 2/3BB
Epoetin Alfa
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3BB
Karenitecin
Baylor College of Medicine
Phase 2BB
ptk787
Pancreatic Cancer Research Team
Phase 2BB
Fluzoparib
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3BB

View all 40 →

Same molecule, other indications

DALPICICLIB ISETIONATE is also rated in:

Breast CancerDormant
BB
Indicative ·
66 / 100
View asset →
Triple Negative Breast Cancer (TNBC)Dormant
B
Indicative ·
63 / 100
View asset →
breast cancerDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →